Quest Diagnostics buys Bert Vogelstein’s Haystack Oncology, just six months after Series A
Quest Diagnostics is buying cancer detection startup Haystack Oncology for $300 million in cash, with plans to launch a new cancer lab test in 2024.
The biotech was developing a minimal residual disease (MRD) test, which is meant to detect cancers that could come back. For Haystack, it’s also a remarkably fast turn from seed round to Series A to a major M&A exit. Started in 2021 with $10 million in seed funding, the biotech announced a $56 million Series A in November.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
